Role of Nanotechnology in Diabetic Management

Author(s): Reena Siwach, Parijat Pandey, Viney Chawla, Harish Dureja*.

Journal Name: Recent Patents on Nanotechnology

Volume 13 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Diabetes Mellitus (DM) has emerged as an epidemic that has affected millions of people worldwide in the last few decades. Nanotechnology is a discipline that is concerned with material characteristics at nanoscale and offers novel techniques for disease detection, management and prevention.

Objective: Diabetes mellitus is an epidemic disease that has affected millions of people globally. Nanotechnology has greatly enhanced the health status by providing non-obtrusive techniques for the management and treatment of diabetic patients.

Method: In diabetes research, the nanotechnology has encouraged the advancement of novel glucose monitoring and several modalities for insulin delivery holding possibilities to enhance the personal satisfaction and life quality for diabetic patients.

Result: Nanoparticles hold a great potential in the areas of drug delivery and are explored as vehicles for orally administered insulin formulations. Glucose biosensors equipped with nanoscale materials such as Quantum Dots (QDs), Carbon Nanotubes (CNTs), Magnetic Nanoparticles (MNPs) etc. have shown greater sensitivity. Nanotechnology in diabetic research is heading towards the novel techniques which can provide continuous glucose monitoring offering accurate information and improving patient’s compliance.

Conclusion: The present review addresses the different aspects of nanoparticles and recent patents related to diabetic management based on nanotechnology.

Keywords: Nanotechnology, nanoparticles, diabetes, nanomedicine, glucose nanosensors, patents.

[1]
Rai VK, Mishra N, Agrawal AK, et al. Novel drug delivery system: An immense hope for diabetics. Drug Deliv 2016; 23(7): 2371-90.
[2]
Fangueiro JF, Silva AM, Garcia ML, et al. Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Eur J Pharm Biopharm 2015; 95: 307-22.
[3]
Subramani K, Pathak S, Hosseinkhani H. Recent trends in diabetes treatment using nanotechnology. Dig J Nanomater Biostruct 2012; 7(1): 85-95.
[4]
Zhang W, Du Y, Wang ML. Noninvasive glucose monitoring using saliva nano-biosensor. Sens Biosensing Res 2015; 4: 23-9.
[5]
DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Nanomed Nanobiotechnol 2015; 7(4): 548-64.
[6]
Piya MK, Tahrani AA, Barnett AH. Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol 2010; 70(5): 631-44.
[7]
Roth GA, Tahiliani S, Neu‐Baker NM, Brenner SA. Hyperspectral microscopy as an analytical tool for nanomaterials. Nanomed Nanobiotechnol 2015; 7(4): 565-79.
[8]
Salek-Maghsoudi A, Vakhshiteh F, Torabi R, et al. Recent advances in biosensor technology in assessment of early diabetes biomarkers. Biosens Bioelectron 2018; 99: 122-35.
[9]
Sadikot SM, Das AK, Wilding J, et al. Consensus recommendations on exploring effective solutions for the rising cost of diabetes. Diabetes Metabolic Syndrome: Clin Res Rev 2017; 11(2): 141-7.
[10]
Akash MS, Rehman K, Chen S. An overview of valuable scientific models for diabetes mellitus. Curr Diabetes Rev 2013; 9(4): 286-93.
[11]
Thassu D, Deleers M, Pathak Y. Nanoparticulate Drug-Delivery Systems: An Overview. Drug Dev Ind Pharm 2008; 34(1): 1-31.
[12]
Boulaiz H, Alvarez PJ, Ramirez A, et al. Nanomedicine: Application areas and development prospects. Int J Mol Sci 2011; 12(5): 3303-21.
[13]
Rees M, Moghimi SM. Nanotechnology: From fundamental concepts to clinical applications for healthy aging. Maturitas 2012; 73(1): 1-4.
[14]
Krol S, Ellis-Behnke R, Marchetti P. Nanomedicine for treatment of diabetes in an aging population: State of the art and future developments. Maturitas 2012; 73(1): 61-7.
[15]
Cash KJ, Clark HA. Nanosensors and nanomaterials for monitoring glucose in diabetes. Trends Mol Med 2010; 16(12): 584-93.
[16]
Decher G. Fuzzy nanoassemblies: Toward layered polymeric multicomposites. Science 1997; 277(5330): 1232-7.
[17]
Hu N, Frueh J, Zheng C, Zhang B, He Q. Photo-crosslinked natural polyelectrolyte multilayer capsules for drug delivery. Colloids Surf A Physicochem Eng Asp 2015; 482: 315-23.
[18]
Decher G, Hong JD. Buildup of ultrathin multilayer films by a self‐assembly process, 1 consecutive adsorption of anionic and cationic bipolar amphiphiles on charged surfaces. In: Makromolekulare Chemie Macromolecular Symposia. Basel: Hüthig & Wepf Verlag 1991; pp. 321-7.
[19]
Balducci S, Sacchetti M, Haxhi J, et al. Physical exercise as therapy for type 2 diabetes mellitus. Diabetes Metab Res Rev 2014; 30(S1): 13-23.
[20]
Jeffery CJ. Engineering periplasmic ligand binding proteins as glucose nanosensors. Nano Rev 2011; 2(1): 5743-9.
[21]
Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: Summary of a comparative effectiveness review. J Manag Care Pharm 2012; 18: 1-7.
[22]
Scognamiglio V. Nanotechnology in glucose monitoring: Advances and challenges in the last 10 years. Biosens Bioelectron 2013; 15(47): 12-25.
[23]
Zhang X, Guo Q, Cui D. Recent advances in nanotechnology applied to biosensors. Sensors 2009; 9(2): 1033-53.
[24]
Eckert MA, Vu PQ, Zhang K, et al. Novel molecular and nanosensors for in vivo sensing. Theranostic 2013; 3(8): 583-94.
[25]
Lee H, Choi TK, Lee YB, et al. A graphene-based electrochemical device with thermo responsive microneedles for diabetes monitoring and therapy. Nat Nanotechnol 2016; 11(6): 566-72.
[26]
Zhi ZL, Khan F, Pickup JC. Multilayer nanoencapsulation: A nanomedicine technology for diabetes research and management. Diabetes Res Clin Pract 2013; 100(2): 162-9.
[27]
Balaconis MK, Clark HA. Gel encapsulation of glucose nanosensors for prolonged in vivo lifetime. J Diabetes Sci Technol 2013; 7(1): 53-61.
[28]
Saran AD, Sadawana MM, Srivastava R, Bellare JR. An optimized quantum dot-ligand system for biosensing applications: Evaluation as a glucose biosensor. Colloids Surf A Physicochem Eng Asp 2011; 384(1-3): 393-400.
[29]
Wang L, Yun X, Stanacevic M, Gouma PI. An acetone nanosensor for non‐invasive diabetes detection.In AIP Conference Proceedings 2009; 1137(1): 206-8.
[30]
Arya AK, Kumar L, Pokharia D, Tripathi K. Applications of nanotechnology in diabetes. Dig J Nanomater Biostruct 2008; 3(4): 221-5.
[31]
Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations-opportunities and limitations. Drug Discov Today Technol 2012; 9(2): 87-95.
[32]
Rahiman S. Nanomedicine Current Trends in Diabetes Management. J Nanomed Nanotechnol 2012; 3(4): 3-8.
[33]
Gundogdu E, Yurdasiper A. Drug transport mechanism of oral antidiabetic nanomedicines. Int J Endocrinol Metab 2014; 12(1): 1-5.
[34]
Ma Z, Lim TM, Lim LY. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm 2005; 293(1-2): 271-80.
[35]
Mesiha MS, Sidhom MB, Fasipe B. Oral and subcutaneous absorption of insulin poly (isobutyl cyanoacrylate) nanoparticles. Int J Pharm 2005; 288(2): 289-93.
[36]
Cui F, Shi K, Zhang L, Tao A, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J Control Release 2006; 114(2): 242-50.
[37]
Bhumkar DR, Joshi HM, Sastry M, Pokharkar VB. Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin. Pharm Res 2007; 24(8): 1415-26.
[38]
Sarmento B, Ribeiro A, Veiga F, et al. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res 2007; 24(12): 2198-206.
[39]
Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 2007; 117(2): 163-70.
[40]
Reis CP, Veiga FJ, Ribeiro AJ, Neufeld RJ, Damgé C. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J Pharm Sci 2008; 97(12): 5290-305.
[41]
Yin L, Ding J, He C, et al. Drug permeability and mucoadhesion properties of thiolate trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 2009; 30(29): 5691-700.
[42]
Sonaje K, Lin YH, Juang JH, et al. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomater 2009; 30(12): 2329-39.
[43]
Zhang N, Li J, Jiang W, et al. Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. Int J Pharm 2010; 393(1-2): 213-9.
[44]
Elsayed A, Al-Remawi M, Qinna N, et al. Chitosan-sodium lauryl sulfate nanoparticles as a carrier system for the in vivo delivery of oral insulin. AAPS PharmSciTech 2011; 12(3): 958-64.
[45]
Zhang X, Sun M, Zheng A, et al. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci 2012; 45(5): 632-8.
[46]
Mukhopadhyay P, Sarkar K, Chakraborty M, et al. Oral insulin delivery by self-assembled chitosan nanoparticles: In vitro and in vivo studies in diabetic animal model. Mater Sci Eng 2013; 33(1): 376-82.
[47]
Liu L, Zhou C, Xia X, Liu Y. Self-assembled lecithin/chitosan nanoparticles for oral insulin delivery: Preparation and functional evaluation. Int J Nanomedicine 2016; 11: 761-9.
[48]
Bhattacharyya A, Mukherjee D, Mishra R, Kundu PP. Preparation of polyurethane-alginate/chitosan core shell nanoparticles for the purpose of oral insulin delivery. Eur Polym J 2017; 92: 294-313.
[49]
Czuba E, Diop M, Mura C, et al. Oral insulin delivery, the challenge to increase insulin bioavailability: Influence of surface charge in nanoparticle system. Int J Pharm 2018; 542(1-2): 47-55.
[50]
Jain AK, Khar RK, Ahmed FJ, Diwan PV. Effective insulin delivery using starch nanoparticles as a potential trans-nasal mucoadhesive carrier. Eur J Pharm Biopharm 2008; 69(2): 426-35.
[51]
Zhang X, Zhang H, Wu Z, et al. Nasal absorption enhancement of insulin using PEG-grafted chitosan nanoparticles. Eur J Pharm Biopharm 2008; 68(3): 526-34.
[52]
Gatti TH, Eloy JO, Ferreira LM, et al. Insulin-loaded polymeric mucoadhesive nanoparticles: Development, characterization and cytotoxicity evaluation. Braz J Pharm Sci 2018; 54(1): 54-62.
[53]
Subramani K. Applications of nanotechnology in drug delivery systems for the treatment of cancer and diabetes. Int J Nanotechnol 2006; 3(4): 557-80.
[54]
Jain S, Saraf S. Influence of processing variables and in vitro characterization of glipizide loaded biodegradable nanoparticles. Diabetes Metabolic Syndrome: Clin Res Rev 2009; 3(2): 113-7.
[55]
Poovi G, Kishore N, Reddy PN. In vitro characterization and in vivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles. Int J Pharm 2010; 396(1-2): 194-203.
[56]
Singh SK, Srinivasan KK, Gowthamarajan K, et al. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur J Pharm Biopharm 2011; 78(3): 441-6.
[57]
Vijayan V, Reddy KR, Sakthivel S, Swetha C. Optimization and characterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patches: In vitro and in vivo studies. Colloids Surf B Biointerfaces 2013; 111: 150-5.
[58]
Lokhande AB, Mishra S, Kulkarni RD, Naik JB. Preparation and characterization of repaglinide loaded ethylcellulose nanoparticles by solvent diffusion technique using high pressure homogenizer. J Pharm Res 2013; 7(5): 421-6.
[59]
Kumar BS, Saraswathi R, Dhanaraj SA. Solid-state characterization studies and effect of PEG 20000 and P90G on particle size reduction and stability of complexed glimepiride nanocrystals. J Young Pharm 2013; 5(3): 83-9.
[60]
Shah SR, Parikh RH, Chavda JR, Sheth NR. Application of Plackett-Burman screening design for preparing glibenclamide nanoparticles for dissolution enhancement. Powder Technol 2013; 235: 405-11.
[61]
Gonçalves LM, Maestrelli F, Mannelli LD, et al. Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide. Eur J Pharm Biopharm 2016; 102: 41-50.
[62]
Ali HS, Hanafy AF. Glibenclamide nanocrystals in a biodegradable chitosan patch for transdermal delivery: Engineering, formulation, and evaluation. J Pharm Sci 2017; 106(1): 402-10.
[63]
Elbahwy IA, Ibrahim HM, Ismael HR, Kasem AA. Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. J Drug Deliv Sci Technol 2017; 38: 78-89.
[64]
HaqAsif A. Harsha S, HodalurPuttaswamy N, E Al-Dhubiab B. An effective delivery system of sitagliptin using optimized mucoadhesive nanoparticles. Appl Sci 2018; 8(6): 861-8.
[65]
Haidar A, Smaoui MR, Legault L, Rabasa-Lhoret R. The role of glucagon in the artificial pancreas. Lancet Diabetes Endocrinol 2016; 4(6): 476-9.
[66]
Pfeiffer EF, Thum C, Clemens AH. The artificial beta cell-a continuous control of blood sugar by external regulation of insulin infusion (glucose-controlled insulin infusion system). Horm Metab Res 1974; 6(5): 339-42.
[67]
Messori M, Cobelli C, Magni L. Artificial Pancreas: From in silico to in-vivo. IFAC-Papers Online 2015; 48(8): 1300-8.
[68]
Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycemic control in patients with type 1 diabetes: A systematic review and meta-analysis of outpatient randomized controlled trials. Lancet Diabetes Endocrinol 2017; 5(7): 501-12.
[69]
Cavalcanti A, Shirinzadeh B, Kretly LC. Medical nanorobotics for diabetes control. Nanomed: Nanotechnol Biol Med 2008; 4(2): 127-38.
[70]
Meetoo D, Lappin M. Nanotechnology and the future of diabetes management. J Diabetes Nurs 2009; 13(8): 288-97.
[71]
Selvaraj K, Gowthamarajan K, Karri VV, et al. Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy. J Drug Target 2017; 25(5): 386-405.
[72]
Moura LI, Dias AM, Carvalho E, de Sousa HC. Recent advances on the development of wound dressings for diabetic foot ulcer treatment - A review. Acta Biomater 2013; 9(7): 7093-114.
[73]
Ramtoola Z. Controlled release biodegradable nanoparticles containing insulin. US Patent 5641515, 1997
[74]
West JL, Sershen SR, Halas NJ, Oldenburg SJ, Averitt RD. Temperature- sensitive polymer/nanoshell composites for photothermally modulated drug delivery. US Patent 6428811, 2002
[75]
Melker RJ, Dennins DM. Application of biosensors for diagnosis and treatment of disease. US Patent 6974706, 2005
[76]
Harnandez FE. Noninvasive glucose monitoring. US Patent 7972862B2, 2011
[77]
Sung HW, Sonaje K, Nguyen HN, Tu H. Pharmacetical composition of nanoparticles. US Patent 8257740B1, 2011.
[78]
Feng Z, Zhang L, Zhang X, He Q, Xiaohong Y. Nasal cavity drop for treating diabetes and preparation method thereofChinese Patent CN101601646B, 2011
[79]
Feng Z, Zhang L, Zhang X, He Q, Xiaohong Y. Oral drug for treating diabetes and preparation method thereofChinese Patent CN101607080B, 2012
[80]
Sung HW, Sonaje K, Nguyen HN, et al. Pharmaceutical composition of nanoparticles. US Patent 8226928B1, 2012.
[81]
Zang J, Hodge WG. Contact lens integrated with a biosensor for the detection of glucose and other components in tears. US Patent 8385998B2, 2013
[82]
Rademcher T, Williams P, Bachmann C, et al. Peptide carrying nanoparticles. US Patent 8568781B2, 2013
[83]
Heon JJ. Sustained drug-release nanoparticle and pharmaceutical composition for preventing or treating diabetes comprising pancreatic islets having modified surface by the nanoparticle Korean Patent KR 101822912B1, 2018
[84]
Gai M, Frueh J, Kudryavtseva VL, Yashchenok AM, Sukhorukov GB. Polylactic acid sealed polyelectrolyte multilayer microchambers for entrapment of salts and small hydrophilic molecules precipitates. ACS Appl Mater Interfaces 2017; 9(19): 16536-45.
[85]
Gai M, Frueh J, Tao T, et al. Polylactic acid nano-and microchamber arrays for encapsulation of small hydrophilic molecules featuring drug release via high intensity focused ultrasound. Nanoscale 2017; 9(21): 7063-70.
[86]
Gai M, Li W, Frueh J, Sukhorukov GB. Polylactic acid sealed polyelectrolyte complex microcontainers for controlled encapsulation and NIR-laser based release of cargo. Colloids Surf B Biointerfaces 2018; 173: 521-8.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 1
Year: 2019
Page: [28 - 37]
Pages: 10
DOI: 10.2174/1872210513666190104122032
Price: $58

Article Metrics

PDF: 43
HTML: 5